LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

Factsheet – European Health Data Space

07/09/2022
FACTSHEET
#VisionforEurope: Innovation, Investment, Excellence

EuropaBio position on the European Health Data Space

The proposal for a European Health Data Space (EHDS) is part of the European Commission’s efforts to harness the benefits of the data economy and unleash the full potential of health data.

The EHDS will put citizens in control of their own health data, whether in their country or cross-border, and held deliver the transformation of healthcare delivery.

The EHDS will also improve the use of health data for research, innovation, and policymaking and create a strong, secure, and trustworthy legal framework for the re-use of health data that will help deliver next-generation treatments.

The European Health Data Space (EHDS) marks a global first in providing federated access to important health data. Placing a central focus on citizens’ control over their data, the EHDS seeks to implement a framework through which data access for primary and secondary use is both clarified and simplified.

The power of data in the healthcare sphere is evident. Realising the potential of healthcare data is a crucial step to ensure the EU is a leader in the development of next generational medicines. The biotechnology industry has stood at the forefront of using digital innovations for many years, having advanced alongside digital technologies.

The EHDS will play a central role in improving the availability of data within a transparent and secure infrastructure. Data collection from across the EU will be valuable in addressing the health challenges facing Europeans, allowing for research and innovation, and collection of insights not possible when necessary data is fragmented.

Priorities

We outline our core priorities for the use of healthcare data in the development of novel biotechnology derived medicines, reflecting on the EHDS legislative proposal:
• EuropaBio encourage the EHDS initiatives that promote the rights and accessibility of citizens to the use of their electronic health data;
• To ensure trust and understanding of healthcare data use, the EHDS implementation should continue to complement the overarching digital transformation (and relevant initiatives);
• Expansion of MyHealth@EU across Member States, and in terms of the services available, is a necessary step to support data portability;
• EuropaBio support standardisation of electronic health records to facilitate the core functioning of the EHDS and support a multi-stakeholder approach to establish relevant criteria;
• A clear framework for the provision of telemedicine services within the context of the EHDS should be explored to enable appropriate access to these necessary services in each Member State, and for all citizens;
• National digital health authorities should receive clear operational guidelines to ensure a harmonised experience across the EU, in particular when dealing with relevant national contact points for digital health to avoid unnecessary fragmentation of data;
• Industry should play an appropriate role as part of the functioning of the European Health Data Space Board;
• Access to the EHDS for private scientific research, and to support development and innovation activities by industry is a welcome recognition of the role the private sector plays;
• We encourage the ability for the EHDS to further our ability to use real world evidence (RWE) in regulation of medicines;
• Maintaining strong intellectual property protections is necessary for a prospering data economy and vibrant innovation system for digital healthcare.

Factsheet - European Health Data Space


Download
European-Health-Data-SpaceDownload
Share
Alexandra Simionca
Alexandra Simionca

Related posts

07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
26/06/2025

Health Biomanufacturing: Feedstock for Preparedness and Resilience


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.